Document Detail

Smokers with the CHRNA lung cancer-associated variants are exposed to higher levels of nicotine equivalents and a carcinogenic tobacco-specific nitrosamine.
MedLine Citation:
PMID:  19010884     Owner:  NLM     Status:  MEDLINE    
A locus at 15q24/15q25.1, which includes the nicotinic acetylcholine receptor A subunits 3 and 5 (CHRNA3 and CHRNA5) genes, has recently been associated with lung cancer risk, self-reported number of cigarettes smoked per day, and a nicotine dependence scale. It is not clear whether the association with lung cancer is direct or mediated through differences in smoking behavior. We used urinary biomarkers to test whether two linked lung cancer risk variants in CHRNA3 (rs1051730) and CHRNA5 (rs16969968) are associated with intensity of smoking and exposure to a tobacco-specific carcinogenic nitrosamine per cigarette dose. We studied 819 smokers and found that carriers of these variants extract a greater amount of nicotine (P = 0.003) and are exposed to a higher internal dose of 4-(methylnitrosamino)-I-(3-pyridyl)-1-butanone (P = 0.03) per cigarette than noncarriers. Thus, smokers who carry the CHRNA3 and CHRNA5 variants are expected to be at increased risk for lung cancer compared with smokers who do not carry these alleles even if they smoked the same number of cigarettes. Number of cigarettes per day, even if it could be accurately assessed, is not an adequate measure of smoking dose.
Loïc Le Marchand; Kiersten S Derby; Sharon E Murphy; Stephen S Hecht; Dorothy Hatsukami; Steven G Carmella; Maarit Tiirikainen; Hansong Wang
Related Documents :
11768174 - Individual differences in smoking: gender and nicotine addiction.
6802384 - Nicotine concentrations in urine and saliva of smokers and non-smokers.
18559554 - Stability of the nicotine metabolite ratio in ad libitum and reducing smokers.
15778004 - Polycyclic aromatic hydrocarbons, carbon monoxide, "tar", and nicotine in the mainstrea...
17852974 - Gender differences in experiencing negative encounters with healthcare: a study of long...
25078464 - Comparison of the metabolic syndrome risk in valproate-treated patients with epilepsy a...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Cancer research     Volume:  68     ISSN:  1538-7445     ISO Abbreviation:  Cancer Res.     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-11-17     Completed Date:  2008-12-10     Revised Date:  2014-09-12    
Medline Journal Info:
Nlm Unique ID:  2984705R     Medline TA:  Cancer Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  9137-40     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Lung Neoplasms / etiology*
Middle Aged
Nerve Tissue Proteins / genetics*
Nicotine / toxicity*
Nitrosamines / toxicity*
Polymorphism, Single Nucleotide
Pyridines / toxicity*
Receptors, Nicotinic / genetics*
Smoking / adverse effects*
Grant Support
P50 DA013333/DA/NIDA NIH HHS; P50 DA013333-05/DA/NIDA NIH HHS; P50 DA13333/DA/NIDA NIH HHS; R01 CA085997/CA/NCI NIH HHS; R01 CA085997-05/CA/NCI NIH HHS; R01 CA85997/CA/NCI NIH HHS
Reg. No./Substance:
0/4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol; 0/CHRNA5 protein, human; 0/Nerve Tissue Proteins; 0/Nitrosamines; 0/Pyridines; 0/Receptors, Nicotinic; 0/nicotinic receptor subunit alpha3; 54-11-5/Nicotine; 64091-91-4/4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Induction of cytoplasmic accumulation of p53: a mechanism for low levels of arsenic exposure to pred...
Next Document:  Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer ...